Trial · NCT00813813
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Neurological Assessment for Motor Function and Reflexes/Sensory | Intradiscal rhGDF-5 (0.25mg) | 0 | participants | ||
| Neurological Assessment for Motor Function and Reflexes/Sensory | Intradiscal rhGDF-5 (1.0mg) | 0 | participants | ||
| Change in Function Assessed by Oswestry Disability Index Change at 12 Months From Baseline | Intradiscal rhGDF-5 (0.25mg) | -10.0 | Standard Deviation 12.00 | units on a scale | |
| Change in Function Assessed by Oswestry Disability Index Change at 12 Months From Baseline | Intradiscal rhGDF-5 (1.0mg) | -17.0 | Standard Deviation 18.00 | units on a scale | |
| Treatment Emergent Adverse Events- Relationship to Study Drug | Intradiscal rhGDF-5 (0.25mg) | 2 | participants | ||
| Treatment Emergent Adverse Events- Relationship to Study Drug | Intradiscal rhGDF-5 (1.0mg) | 1 | participants | ||
| Change in Pain Visual Analog Scale (VAS) at 12 Months From Baseline | Intradiscal rhGDF-5 (0.25mg) | -2.0 | Standard Deviation 2.00 | units on a scale | |
| Change in Pain Visual Analog Scale (VAS) at 12 Months From Baseline | Intradiscal rhGDF-5 (1.0mg) | -3.0 | Standard Deviation 2.00 | units on a scale | |
| Change in Physical Component Summary of Quality of Life Measure Assessed by Short-Form 36 at 12 Months From Baseline | Intradiscal rhGDF-5 (0.25mg) | 5.0 | Standard Deviation 6.00 | units on a scale | |
| Change in Physical Component Summary of Quality of Life Measure Assessed by Short-Form 36 at 12 Months From Baseline | Intradiscal rhGDF-5 (1.0mg) | 8.0 | Standard Deviation 10.00 | units on a scale | |
| Change in Mental Component Summary Quality of Life Measure Assessed by Short Form SF-36 at 12 Months From Baseline | Intradiscal rhGDF-5 (0.25mg) | 7.0 | Standard Deviation 8.00 | units on a scale | |
| Change in Mental Component Summary Quality of Life Measure Assessed by Short Form SF-36 at 12 Months From Baseline | Intradiscal rhGDF-5 (1.0mg) | 3 | Standard Deviation 12.00 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00813813/results